Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Condition:   Diffuse Large B-cell Lymphoma Interventions:   Drug: Polatuzumab vedotin (PV);   Drug: Rituximab;   Drug: Hyaluronidase;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Dexamethasone;   Drug: GCSF Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials